E. Baldini

G. Fontanini, A. Mussi, M. Lucchi, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Paclitaxel/epirubicin/etoposide in patients with extensive-disease small-cell lung cancer (SCLC)

A. Chella, C. Angeletti, P. Conte, 1999 .

ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin

G. Fontanini, C. Boni, E. Baldini, 2013, British Journal of Cancer.

Sequential chemoradiation therapy with vinorelbine, ifosfamide, and cisplatin in stage IIIB non-small cell lung cancer: a phase II study.

C. Tibaldi, P. Conte, L. Cionini, 2000, Seminars in oncology.

Benefit from a high dose of gefitinib in a woman with lung adenocarcinoma and an epidermal growth factor receptor tyrosine-kinase acquired mutation.

G. Fontanini, L. Boldrini, T. Prochilo, 2008, Molecular medicine reports.

Long-term results of combined-modality therapy for inflammatory breast carcinoma.

T. Prochilo, E. Baldini, R. Lionetto, 2004, Clinical breast cancer.

A Randomized Trial of Chemotherapy with or without Estrogenic Recruitment in Locally Advanced Breast Cancer

A. Rubagotti, P. Conte, R. Rosso, 1997, Tumori.

Chemotherapy with or without estrogenic recruitment in metastatic breast cancer. A randomized trial of the Gruppo Oncologico Nord Ovest (GONO).

D. Amadori, R. Demicheli, A. Rubagotti, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Filgrastim and lack of support of intensive adjuvant chemotherapy for high-risk breast cancer patients.

C. Tibaldi, P. Conte, E. Baldini, 1997, American journal of clinical oncology.

Informal Caregiving Burden in Advanced Non-small Cell Lung Cancer: The HABIT study

C. Gridelli, S. Novello, S. Palazzo, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: a phase II study.

C. Tibaldi, P. Conte, E. Baldini, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors

C. Tibaldi, E. Baldini, A. Lunghi, 2017, World journal of clinical oncology.

C. Tibaldi, G. Fasola, G. Ceresoli, 2019, Lung cancer.

Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)

D. Bruzzese, G. Arpino, A. Fabi, 2020, ESMO open.

Paclitaxel combinations as front-line and salvage chemotherapy regimens in advanced breast cancer.

C. Tibaldi, P. Conte, E. Baldini, 1996, Seminars in oncology.

Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.

C. Tibaldi, F. Innocenti, O. Biadi, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination chemotherapy with vinorelbine, ifosfamide, and cisplatin: a phase II study in stage IIIB-IV non-small cell lung cancer.

A. Chella, C. Angeletti, C. Tibaldi, 1994, Seminars in oncology.

In vivo cytokinetic effects of recombinant human growth hormone (rhGH) in patients with advanced breast carcinoma.

P. Conte, F. Minuto, E. Baldini, 1994, Journal of biological regulators and homeostatic agents.

Stimulation of Human Breast Cancer in Vivo

D. Amadori, A. Rubagotti, P. Conte, 1993, Annals of the New York Academy of Sciences.

Relationship of variations in tumor cell kinetics induced by primary chemotherapy to tumor regression and prognosis in locally advanced breast cancer

L. Merlini, P. Conte, R. Rosso, 2004, Breast Cancer Research and Treatment.

A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.

C. Tibaldi, P. Conte, E. Baldini, 1996, Seminars in oncology.

Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.

C. Tibaldi, A. Ardizzoni, L. Boni, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer: treatment rationale and protocol design of the GOIRC-AIFA FARM6PMFJM trial.

C. Tibaldi, L. Crinò, A. Ardizzoni, 2015, Clinical lung cancer.

CheckMate 384: Phase IIIb/IV trial of nivolumab (nivo) 480 mg Q4W versus 240 mg Q2W after ≤ 12 months of nivo in previously treated advanced NSCLC.

N. Reinmuth, K. O'Byrne, S. Rabindran, 2019, Journal of Clinical Oncology.

Phenotypic and functional characteristics of tumor‐associated lymphocytes in patients with malignant ascites receiving intraperitoneal infusions of recombinant interleukin‐2 (ril‐2)

L. Moretta, M. Sertoli, A. De Maria, 1989, International journal of cancer.

Intraperitoneal infusion of interleukin-2 in patients with malignant ascites: Phenotypic and functional effects on tumor-associated lymphocytes

L. Moretta, E. Baldini, G. Melioli, 1988, La Ricerca in clinica e in laboratorio.

Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study*

C. Orlandini, R. Danesi, S. Fogli, 2001, Breast Cancer Research and Treatment.

Accelerated chemotherapy with or without GM-CSF for small cell lung cancer: a non-randomised pilot study.

A. Ardizzoni, P. Mazzanti, M. Ferrarini, 1990, European journal of cancer.

Pharmacoepigenetics in gastrointestinal tumors: MGMT methylation and beyond.

G. Masi, A. Falcone, L. Fornaro, 2016, Frontiers in bioscience.

Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients.

C. Tibaldi, P. Conte, E. Baldini, 1996, Seminars in oncology.

Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.

C. Tibaldi, O. Biadi, P. Conte, 1996, Seminars in oncology.

Cyclin‐D1 expression in node‐positive (N+) and node‐negative (N−) infiltrating human mammary carcinomas

G. Bevilacqua, E. Baldini, P. Collecchi, 1999, International journal of cancer.

Cyclin A and E2F1 overexpression correlate with reduced disease-free survival in node-negative breast cancer patients.

C. Orlandini, G. Bevilacqua, T. Prochilo, 2006, Anticancer research.

Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never‐Smokers and EGFR‐Mutant Patients

E. Vasile, G. Fasola, D. Galetta, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients.

Federico Innocenti, Pier Franco Conte, Guido Bocci, 2002, British journal of clinical pharmacology.

Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma.

C. Orlandini, G. Bevilacqua, E. Baldini, 2009, Human pathology.

Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer.

P. Bruzzi, F. Mosca, T. Prochilo, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP).

C. Tibaldi, M. Rinaldi, F. de Marinis, 1998, British Journal of Cancer.

Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force.

F. de Marinis, P. Bruzzi, A. Ardizzoni, 1995, British Journal of Cancer.

Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC)

C. Tibaldi, A. Ardizzoni, L. Boni, 2001, British Journal of Cancer.

Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM)

A. Marchetti, F. Cappuzzo, A. Rossi, 2019, Tumori.

Gemcitabine, ifosfamide and Navelbine (GIN): a platinum-free combination in advanced non-small-cell lung cancer (NSCLC)

C. Tibaldi, A. Ardizzoni, L. Boni, 2002, Cancer Chemotherapy and Pharmacology.

Biologic and clinical effects of continuous infusion interleukin‐2 in patients with non‐small cell lung cancer

A. Ardizzoni, S. Ferrini, R. Rosso, 1994, Cancer.

Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.

P. Bruzzi, R. Rosso, M. Venturini, 2005, Journal of the National Cancer Institute.

Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer.

E. Scarpi, D. Amadori, N. Biglia, 2015, European journal of cancer.

Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: a systematic review.

G. Masi, A. Falcone, L. Fornaro, 2014, World journal of gastroenterology.

Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach

V. Poletti, S. Novello, G. Banna, 2019, PloS one.

Oral Anticancer Therapy Project: Clinical utility of a specific home care nursing program.

G. Tortora, V. Zagonel, G. Tonini, 2016, Journal of clinical nursing.

Differences in the Availability of New Anti-Cancer Drugs for Italian Patients Treated in Different Regions. Results of Analysis Conducted by the Italian Society of Medical Oncology (AIOM)

P. Tagliaferri, L. Crinò, G. Beretta, 2010, Tumori.

Trousseau’s Syndrome Anticipating Lung Adenocarcinoma: A Combination of Novel Direct Oral Anticoagulant and Osimertinib to Treat It

C. Tibaldi, E. Baldini, I. Pecora, 2021, Global Journal of Cancer Case Reports.

EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition

E. Vasile, A. Chella, C. Tibaldi, 2014, Journal of experimental & clinical cancer research : CR.

Double-blind randomized trial of lorazepam versus placebo with methylprednisolone for control of emesis due to non-cisplatin containing chemotherapy.

P. Bruzzi, A. Rubagotti, R. Rosso, 1990, Journal of chemotherapy.

Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto

C. Tibaldi, A. Ardizzoni, L. Boni, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti‐HER2 agents in the real world setting

S. Barni, N. Tinari, G. Ciliberto, 2019, International journal of cancer.

Concomitant versus sequential administration of epirubicin and paclitaxel as first‐line therapy in metastatic breast carcinoma

M. Costantini, P. Bruzzi, T. Prochilo, 2004, Cancer.

Epirubicin/vinorelbine as first line therapy in metastatic breast cancer

C. Tibaldi, L. Fioretto, P. Conte, 1998, Breast Cancer Research and Treatment.

“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome

P. Marchetti, F. Montemurro, V. Rossi, 2016, Oncotarget.

Mutational Analysis in Cytological Specimens of Advanced Lung Adenocarcinoma: A Sensitive Method for Molecular Diagnosis

G. Fontanini, L. Boldrini, S. Gisfredi, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

1318PItalian nivolumab expanded access programme in non-squamous non-small cell lung cancer patients: Real-world results in never smokers and EGFR positive patients

E. Vasile, G. Ceresoli, R. Chiari, 2017 .

Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer

A. Chella, G. Alí, G. Fontanini, 2023, Frontiers in Oncology.

Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer

E. Scarpi, D. Amadori, N. Biglia, 2011, Breast Cancer Research and Treatment.

Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study

G. Altavilla, M. Venturini, S. Siena, 2012, BMC Cancer.

Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST)

R. Labianca, E. Matano, C. Boni, 2012, British Journal of Cancer.

Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group.

P. Bruzzi, M. Venturini, B. Dozin, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.